PDF(Pubmed)
Abstract：
BACKGROUND: Both cervical cancer and cervical intraepithelial neoplasia (CIN) are associated with human papillomavirus (HPV) infection at different anogenital sites, but the infection features of high-risk (HR) HPVs at these sites and their association with cervical lesions have not been well characterized. Given the limitation of cervical HPV 16/18 test in screening patients with high-grade CIN (CIN 2+), studies on whether non-16/18 HR-HPV subtype(s) have potential as additional indicator(s) to improve CIN 2+ screening are needed.
METHODS: The infection of 15 HR-HPVs in vulva, anus, vagina, and cervix of 499 Chinese women was analyzed, and CIN lesion-associated HR-HPV subtypes were revealed.
RESULTS: In addition to the well-known cervical-cancer-associated HPV 16, 52, and 58, HPV 51, 53, and 56 were also identified as high-frequency detected subtypes prevalently and consistently present at the anogenital sites studied, preferentially in multi-infection patterns. HPV 16, 52, 58, 56, and 53 were the top five prevalent subtypes in patients with CIN 2+. In addition, we found that cervical HPV 33/35/52/53/56/58 co-testing with HPV 16/18 might improve CIN 2+ screening performance.
CONCLUSIONS: This study provided a new insight into HR-HPV screening strategy based on different subtype combinations, which might be used in risk stratification clinically.
METHODS: The infection of 15 HR-HPVs in vulva, anus, vagina, and cervix of 499 Chinese women was analyzed, and CIN lesion-associated HR-HPV subtypes were revealed.
RESULTS: In addition to the well-known cervical-cancer-associated HPV 16, 52, and 58, HPV 51, 53, and 56 were also identified as high-frequency detected subtypes prevalently and consistently present at the anogenital sites studied, preferentially in multi-infection patterns. HPV 16, 52, 58, 56, and 53 were the top five prevalent subtypes in patients with CIN 2+. In addition, we found that cervical HPV 33/35/52/53/56/58 co-testing with HPV 16/18 might improve CIN 2+ screening performance.
CONCLUSIONS: This study provided a new insight into HR-HPV screening strategy based on different subtype combinations, which might be used in risk stratification clinically.
摘要：
背景：宫颈癌和宫颈上皮内瘤变（CIN）均与不同肛门生殖器部位的人乳头瘤病毒（HPV）感染有关，但这些部位的高危(HR)HPV的感染特征及其与宫颈病变的关系尚未得到很好的表征.鉴于宫颈HPV16/18检测在筛查高级别CIN（CIN2+）患者中的局限性，需要研究非16/18HR-HPV亚型是否有可能作为改善CIN2+筛查的额外指标.
方法：外阴15例HR-HPV感染,肛门,阴道,分析了499名中国女性的子宫颈，发现与CIN病变相关的HR-HPV亚型。
结果：除了众所周知的宫颈癌相关HPV16、52和58之外，HPV51、53和56也被鉴定为高频率检测的亚型，并且始终存在于所研究的肛门生殖器部位。优先在多重感染模式中。HPV16、52、58、56和53是CIN2+患者的前5种流行亚型。此外,我们发现宫颈HPV33/35/52/53/56/58与HPV16/18联合检测可能会提高CIN2+筛查效果.
结论：这项研究为基于不同亚型组合的HR-HPV筛查策略提供了新的见解，可用于临床风险分层。
方法：外阴15例HR-HPV感染,肛门,阴道,分析了499名中国女性的子宫颈，发现与CIN病变相关的HR-HPV亚型。
结果：除了众所周知的宫颈癌相关HPV16、52和58之外，HPV51、53和56也被鉴定为高频率检测的亚型，并且始终存在于所研究的肛门生殖器部位。优先在多重感染模式中。HPV16、52、58、56和53是CIN2+患者的前5种流行亚型。此外,我们发现宫颈HPV33/35/52/53/56/58与HPV16/18联合检测可能会提高CIN2+筛查效果.
结论：这项研究为基于不同亚型组合的HR-HPV筛查策略提供了新的见解，可用于临床风险分层。
